Prof. Dr. Thomas Forst
Director Medical Science
clinical research
Profil answer for diabetes
Germany
Biography
Susanne has a special focus on biosimilars and is very experienced in conducting trials in this field. Her efforts drive forward the achievements of Profil's project development team. Thomas has more than 20 years experience in clinical research with special expertise in the field of diabetes mellitus and its vascular complications. He is lecturing at the Johannes Gutenberg University in Mainz as a Professor for Internal Medicine/Endocrinology. Professor Forst is a member of the American, the European and the German Diabetes Association and serves as an editorial board member of several national and international trade journals. He has authored or co-authored in excess of 150 original articles in peer reviewed international journals.
Research Interest
Hypoglycemia risk related to double dose is markedly reduced with basal insulin peglispro versus insulin glargine in patients with type 2 diabetes mellitus in a randomizedBolusing frequency and amount impacts glucose control during hybrid closed-loop. trial: IMAGINE 8.The effect of empagliflozin on muscle sympathetic nerve activity in patients with type 2 diabetes mellitus.
